share_log

Stifel Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $26

Stifel Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $26

Stifel以买入评级开始对Neumora Therapeutics进行报道,宣布目标股价为26美元
Benzinga ·  2023/10/10 05:47

Stifel analyst Paul Matteis initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $26.

Stifel分析师Paul Matteis对Neumora Treeutics(纳斯达克:NMRA)的报道给予买入评级,并宣布目标价为26美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发